DNA graphic

Organizational Structure

Lupus Therapeutics Board of Directors:

Kelly McVearry, PhD, MA, Ed.M. has two decades of experience leading the design, development, due diligence and commercialization of life science and information technologies. She has led two turnarounds, launched three commercial and nonprofit ventures, and been a senior advisor to Fortune 100 advanced technology companies, biotechnology and software start-ups, private equity firms, venture capitalists, and institutional fund managers. Earlier, Kelly was a principal investigator and co-investigator for multi-site clinical trials and hypothesis-driven prospective studies of women’s health, neurodevelopment, drug exposure, and neuro-teratology. Kelly currently serves as the Chair of the Lupus Therapeutics Board of Directors.

William Wolfe is the co-founder, Chairman and CEO of First Washington Realty, Inc., a privately held real estate investment advisory firm specializing in the ownership of neighborhood and community shopping centers in major metropolitan areas throughout the United States. He is responsible for overseeing all aspects of the company’s investment activities. Prior to entering the real estate industry, Mr. Wolfe served in the Executive Office of the President of the United States. Mr. Wolfe is on the Board of the Lupus Research Alliance and Lupus Therapeutics. He is a Trustee of The Washington Institute for Near East Policy, and he is a member of the International Council of Shopping Centers and the World Presidents’ Organization. He has served as a Board member of Washington Heart, the University of Maryland School of Public Affairs, the National Bank of Commerce and the Corporate Board of the Johns Hopkins University Carey Business School. In 1971, Mr. Wolfe co-founded The Key Program, Inc., a New England-based youth service agency that provides residential and non-residential programming to at-risk youth, and he served as Key’s Chairman for 25 years. Since inception, Key has provided services to over 200,000 young people and their families, and William J. Wolfe Scholarships have been awarded to over 500 students to attend 40 colleges and universities.

Thomas Daniel, MD is Chairman & President of Vividion Therapeutics, a venture partner at ARCH Venture Partners, and Director at Zafgen, Inc., JUNO Therapeutics, Magenta Therapeutics, and VIR Bio. Earlier, Dr. Daniel served as President/Chairman, Research and Early Development of Celgene Corporation. He also served as Chief Scientific Officer at Ambrx Inc.; as Vice President, Research at Amgen Inc.; and as Senior Vice President of Discovery Research at Immunex. A nephrologist and former academic investigator, Dr. Daniel currently serves as a member of the Biomedical Science Advisory Board of Vanderbilt University Medical Center.

Brian Kotzin, MD has been committed to patient care, research, and teaching during his 25-year academic career. With his interest in developing novel therapeutics for rheumatic diseases, Dr. Kotzin joined Amgen Inc. in 2004 as Vice President of Global Clinical Development and Head of the Inflammation Therapeutic Area. He later served at Amgen as Vice President and Head of Medical Sciences, an integrated department comprised of Early Clinical Development, Molecular Sciences, Imaging Sciences, Clinical Immunology, and Computational Biology. Since 2015, Dr. Kotzin has been a consultant with a focus on developing new therapeutics for lupus and other autoimmune and inflammatory diseases. He also currently serves as a Senior Vice President at Nektar Therapeutics.

Joseph Mauriello retired in 2006 as Deputy Chairman & COO of KPMG, after 40 years in various leadership positions. He serves on the boards of several institutions, including XL Capital Ltd., Fidelity Funds, Arcadia Resources, the School of Risk Management, Insurance and Actuarial Sciences (former College of Insurance) at the Peter J. Tobin College of Business at St. John’s University in New York. He is also a member of the Board of Trustees of the St. Barnabas Medical Center in Livingston, NJ.

Jennie DeScherer is an active Board member of the Lupus Research Alliance having helped lead its predecessor organizations – S.L.E. Lupus Foundation (S.L.E.) and the Lupus Research Institute (LRI) – since their early years. Ms. DeScherer remains involved in developing virtually all fundraising events and program initiatives at the Lupus Research Alliance. In addition to her work on behalf of the lupus community, Ms. DeScherer serves on the Board of the Spoleto Festival USA. She is also an active participant in and patron of the arts and other cultural institutions.

Alexander von Perfall joined Royalty Pharma in 2009 as Vice President, Investor Relations & Public Affairs. Earlier, Mr. von Perfall was the Co-Founder and Chief Network Officer of XTF, a start-up exchange-traded fund ratings agency. Mr. von Perfall started his career as a talent scout with BMG Entertainment where he oversaw the artistic development of a number of critically and commercially successful recording artists, followed by corporate venturing positions with Bertelsmann AG, where he initiated and oversaw early-stage investments in IP-based media and entertainment companies.

Cantey Boyd serves as a Managing Director of Baker Brothers Investments, a fund management company focused on long-term investments in life-sciences companies. Before joining Baker Brothers in 2005, Ms. Boyd worked in investment banking at Deutsche Bank Alex. Brown.

Kenneth Farber serves as the President and CEO of the Lupus Research Alliance. Ken is a graduate of Clark University, with a Juris Doctor from the Fordham University School of Law. He has spent 40 years in the non-profit world, working with and for voluntary health agencies and private foundations.

Ken began his career at Juvenile Diabetes Research Foundation (JDRF), in several different positions, including 10 years as Director of Sponsored Research and nine years as Executive Director.

After his work at JDRF, Ken served as Executive Vice President of Ben-Gurion University of the Negev, founded by Israel’s first Prime Minister and located in the biblical city of Beer-Sheva, Israel.

In 1999, when Robert Wood Johnson was starting a lupus-based research organization, Ken returned to the United States to help get the new organization, the Alliance for Lupus Research (ALR), off the ground, serving as President of the ALR. Ken consults for and sits on the boards of several health-related organizations, including the Nancy Lurie Marks Family Foundation headquartered in Wellesley, Massachusetts. Under Ken’s leadership, the ALR dedicated itself to its credo of supporting research into the cause, cure, treatment, and prevention of lupus and its secondary complications, and in 2016 merged with the Lupus Research Institute and S.L.E. Lupus Foundation. Today, the Lupus Research Alliance gives more money to lupus research than any non-governmental organization in the world.

Albert Roy serves as the Executive Director of Lupus Therapeutics and is responsible for the planning, directing, and coordinating the organization’s core business operations and the Alliance’s clinical trial endeavors. Al brings more than 18 years of non-profit and medical research experience to the organization. Previously, Al was Vice President of Operations and Research Programs at CureSearch for Children’s Cancer, a multi-million dollar public charity whose mission is to support targeted and innovative children’s cancer research. CureSearch served as the fiscal, administrative and philanthropic agent for the world’s largest pediatric cancer clinical trials research network, the Children’s Oncology Group (COG). During his tenure there, Mr. Roy managed a clinical research portfolio exceeding $50 million per year-and coordinated the formation of the COG through strategic partnerships with more than 200 academic research medical centers throughout North America to conduct Phase I, II and III industry-led and investigator-initiated pediatric cancer clinical trials. Mr. Roy is a graduate of Ithaca College and received his Master’s Degree from Johns Hopkins University.

Lupus Therapeutics Staff

Albert T. Roy
Executive Director
Phone: 646-884-6071
Email: aroy@lupustherapeutics.org

Angela Britton
Director, Clinical Operations
Phone: 646-884-6038
Email: abritton@lupustherapeutics.org

Caroline Donovan
Manager, Patient Engagement
Phone: 646-884-6037
Email: cdonovan@lupustherapeutics.org

Jennifer Gold
Administrative & Data Coordinator
Phone: 646-884-6039
Email: jgold@lupustherapeutics.org

LuCIN Committees


Steering Committee

Kenneth Kalunian, MD (Chair), University of California – San Diego
Maria Dall’Era, MD (Vice Chair), University of San Francisco – San Francisco
Cindy Aranow, MD, Feinstein Institute for Medical Research
Anca Askanase, MD, Columbia University Medical Center
Jane Salmon, MD Hospital for Special Surgery
Mark Matsos, MD, McMaster University of Health Sciences, Canada
Paul Fortin, MD, University of Laval, Canada
Maureen McMahon, MD, University of California – Los Angeles
Saira Sheikh, MD, University of North Carolina, Chapel Hill
David Karp, MD, University of Texas Southwestern Medical Center
Sam Lim, MD, Emory University
Nora Singer, MD, Case Western Reserve University – The MetroHealth System
Rosalind Ramsey-Goldman, MD, Northwestern University, Illinois

Drug Candidate Vetting Sub-Committee
Mary Collins, PhD (Co-Chair)
Betty Diamond, MD (Co-Chair), Feinstein Institute for Medical Research
Brian Kotzin, MD
Jeff Browning, PhD, Boston University
Peter Isakson, PhD
Bill Robinson, MD, PhD, Stanford University
V. Michael Holers, MD, PhD, University of Colorado – Denver
Michelle Kahlenberg, MD, University of Michigan
Ethan Shevach, MD, National Institutes of Health, NIAID
Bevra Hahn, MD, University of California – Los Angeles
Jill Buyon, MD, New York University
David Wofsy, MD, University of California – San Francisco

Protocol Review & Design Sub-Committee
Richard Furie, MD (Co-Chair), Northwell Health
Diane Kamen, MD (Co-Chair), Medical University of South Carolina
Kyriakos Kirou, MD, Hospital for Special Surgery
Murray Urowitz, MD, University of Toronto
Meenakshi Jolly, MD, Rush University
Brad Rovin, MD, Ohio State University
Victoria Werth, MD, University of Pennsylvania
Nancy Olsen, MD, Penn State University/Hershey Medical Center
Andras Perl, MD, State University of New York – Syracuse
Christine Peschken, MD, University of Manitoba
Elena Massarotti, MD, Brigham & Woman’s Hospital
Arthur Kavanaugh, MD, University of California – San Diego
Mary Mahieu, MD, Northwestern University
Arezou Khosroshahi, MD, Emory University
Cristina Arriens, MD, Oklahoma Medical Research Foundation
Maria Antonelli, MD, Case Western Reserve University
Mimi Kim, PhD, Albert Einstein College of Medicine

Section leaders include:
Musculoskeletal Outcomes in Lupus Trials
Arthur Kavanaugh, MD, University of California – San Diego

Mucocutaneous Outcomes in Lupus Trials
Victoria Werth, MD, University of Pennsylvania

Lupus Nephritis Trials
Brad Rovin, MD, Ohio State University

Biomarkers in Lupus Trials
Andras Perl, MD, State University of New York

Patient Reported Outcomes in Lupus Trials
Meenakshi Jolly, MD, Rush University

Addressing Health Disparities in Lupus Trials
Christine Peschken, MD, University of Manitoba

Methodology and Outcomes for Lupus Trials
Mimi Kim, PhD, Albert Einstein College of Medicine

Education & Certification Sub-Committee
Anca Askanase, MD (Co-Chair), Columbia University Medical Center
Cynthia Aranow, MD, (Co-Chair), Feinstein Institute for Medical Research
Matt Baker, MD, Stanford University
Eliza Chakravarty, MD, Oklahoma Medical Research Foundation
Kyriakos Kirou, MD, Hospital for Special Surgery
Sam Lim, MD, Emory University
Joe McCune, MD, University of Michigan
Amit Saxena, MD, New York University

Resource Sub-Committee
Rosalind Ramsey-Goldman, MD (Co-Chair), Northwestern University
Paul Fortin, MD, (Co-Chair), University of Laval, Canada
Saira Sheikh, MD, University of North Carolina, Chapel Hill
Jorge Sanchez-Guerrero, MD, UHN Canada
Jennifer Grossman, MD, University of California – Los Angeles
Bobby Han, MD, University of Washington
Fotios Koumpouras, MD, Yale University
Maria Carpintero, MD, University of Miami
Meggan Mackay, MD, Feinstein Institute for Medical Research

IRB Sub-Committee
Nora Singer, MD (Co-Chair), Case Western Reserve University – The MetroHealth System
David Karp, MD (Co-Chair), University of Texas Southwestern Medical Center
Elena Massarotti, MD, Brigham and Women’s Hospital

Learn more about ongoing clinical trials being conducted within LuCIN